HTB

Resistance

Publications launched at IAS 2017

Pre-ART drug resistance in rural South Africa but limited clinical impact with good adherence

No increased resistance with once daily dosing of abacavir and 3TC than twice daily dosing in the ARROW trial

Achieving viral suppression with HIV multi-drug resistance: peg-interferon and valaciclovir as part of rescue therapy

No transmission of integrase-resistant HIV seen in California cohort

Transmitted drug resistance in HIV positive pregnant women

XXIV International HIV Drug Resistance Workshop
, 21-22 February 2015, Seattle, Washington

Prevalence of transmitted drug resistance globally: highest in Australia, US and some European countries but between-country differences in all regions

Higher rates of K65R in non-B subtype in large UK cohort and implications of tenofovir resistance in resource-limited settings

Drug resistance and integrase inhibitors: potential impact of HIV subtype

Drug resistance in children after PMTCT and early treatment

Genotyping using dried blood spots in rural South African setting

NNRTI resistance found in 12% of people stopping treatment with undetectable viral load: implications for stock-outs

Persistence of transmitted drug resistance mutations suggests source partners may be treatment-naive

Dolutegravir update: treatment-naive and -experienced patients and drug resistance

Higher intracellular concentrations with tenofovir alafenamide (TAF) overcomes K65R and other key NRTI resistance in vitro

Tentative phenotypic cut offs for dolutegravir: guidance for use with integrase resistance

S/GSK744 and long-acting formulation indicate broadly similar resistance profile to dolutegravir

ddI resistance in South African children failing an abacavir or d4T based first-line regimen

US label changes for rilpivirine and Eviplera follows EU caution on high baseline viral load: new summary on drug resistance

In vitro resistance profile for BMS 986001

Recombination dynamics in case of MDR sub-type D following superinfection with wild-type sub-type B

Defective viral reservoir populations is common in patients on long-term suppressed ART

First case report of transmission with five-class resistance

New data on the Berlin patient: interpret with caution

Free online resource for treatment decisions without access to genotype resistance tests

Minority M184V variants detected in women after receiving 3TC/FTC and LPV/r-containing regimens in pregnancy

Novel mutations and shifting susceptibility to darunavir and tipranavir

Darunavir-associated mutations in PI-naive and PI-experienced children in the UK

Rate of accumulation of TAMS slow in patients continuing on failing AZT or d4T containing regimens

Transmitted multidrug-resistant HIV persists in PBMC DNA for years

Low-level Q148R in people without integrase inhibitor experience

Cut-offs suggested for predicting efavirenz failure with low-level K103N

Lower M184V rates with FTC/TDF than with 3TC/TDF

HBV resistance to lamivudine at undetectable and low levels of viremia

Integrase inhibitor resistance and cross-resistance: weighing viral fitness and the option to benefit from second-generation compounds

Understanding etravirine susceptibility: new weighted genotype score and phenotypic cut-offs

Lack of virological impact of treatment intensification in suppressed patients supports latent viral reservoir as source of residual viraemia

NNRTI resistance in infants prophylaxed with single-dose nevirapine varies by the timing of infection

Detecting viral tropism: impact of a more sensitive Trofile (ES) assay

Low frequency K103N mutations are associated with poor virological response to NNRTI based therapy

Background drugs and low maraviroc levels explain resistance in Motivate studies

Dual-class mutations affection RTI and NNRTI may be common in experienced patients

Integrase inhibitors and resistance

Treatment failure and tropism changes in maraviroc trial related to previously undetected CXCR4, rather than a mutational shift from CCR5

Mechanisms of failure to CCR5 inhibitors is not explained by mutation in the V3 loop, cross-resistance between CCR5 inhibitors is likely

Higher risk of resistance using lopinavir/r monotherapy

Macaque study shows similar protection from rectal exposure using 2-hour pre- and 24-hour post exposure prophylaxis with tenofovir plus FTC compared to daily regimen

Thirteen NNRTI mutations linked to resistance to etravirine (TMC-125)

Few integrase inhibitor (INI) mutations in INI-naive people

Response to darunavir, tipranavir, or lopinavir after atazanavir failure

Upper and lower clinical cutoffs proposed for darunavir

Accuracy of Monogram’s Trofile assay in determining tropism and new tropism assays in development

Several genotyping systems offer hope as tropism predictors

Raltegravir (MK-0518) phase 3 trials show successful viral suppression in multi-drug resistant patients

Unexpectedly high rate of K65R mutation in patients failing first-line d4T-containing regimens in Thailand

Multi-drug resistance in vertically infected children

MK-0518 demonstrates potent efficacy in patients with triple-class resistant virus: 24 week results

Cell studies predict cross-resistance among integrase inhibitors

Report from the 10th Annual UK Resistance Meeting, 21 September 2006, London

15th International Drug Resistance Workshop, 13-17 June 2006, Sitges, Spain

Resistance implications of monotherapy with lopinavir/r (Kaletra)

Ritonavir reduces virological failure and resistance in treatment naive patients treated with atazanavir

Resistance to darunavir (TMC-114): predicting responses for treatment experienced patients

Epidemiological studies and transmission of resistance: evidence for optimism – or issues with interpretation?

Post navigation